Skip to content

Study · Animal study (in vivo) · rat · 2003

2 results

[The dentate gyrus neurogenesis: a common therapeutic target for Alzheimer disease and senile depression?].

Tatebayashi Y

Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica1 Jan 2003Cited by 2 (Europe PMC)

PMID12806901 (opens in a new tab)PepBankPUB-12806901

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, Cerebrolysin enhanced neurogenesis.

    In plain wordsIn rats, Cerebrolysin increased new neuron formation.

    Outcome
    IncreaseNeurogenesis
    Study

    ratn: not reported in source

    adult female rats
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that Cerebrolysin, an anti-dementia drug that improves the activity of daily living of Alzheimer disease (AD) patients, can enhance neurogenesis and spatial learning of adult female rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, Cerebrolysin enhanced spatial learning.

    In plain wordsIn rats, Cerebrolysin improved spatial learning.

    Outcome
    IncreaseSpatial learning
    Study

    ratn: not reported in source

    adult female rats
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that Cerebrolysin, an anti-dementia drug that improves the activity of daily living of Alzheimer disease (AD) patients, can enhance neurogenesis and spatial learning of adult female rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.